Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q1 2019 Earnings Presentation
12 slides from Anika Therapeutics's earnings presentation, May 2, 2019
Slide 1: First Quarter 2019 Earnings Call Presentation
First Quarter 2019 Earnings Call Presentation May 2, 2019 Nasdaq: ANIK
Slide 2: Safe Harbor Statements
Safe Harbor Statements Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Foundation for Long-Term Growth
Foundation for Long-Term Growth 2019: A Transformational Year for Anika People Products Performance Recruiting and retaining Innovative therapies Driving growth and profitability high-end talent to drive developed & commercialized to deliver maximum value for innovation and a culture of to meet the
Slide 4: Expanding R&D & Commercial Infrastructure
Expanding R&D & Commercial Infrastructure Strengthening Foundation for Long-Term Value Creation R&D: Added VP of Research & Development to accelerate pipeline and leverage technology platform U.S. Commercial: Added VP of U.S. Sales to lead the launch and build out of hybrid commercial model Internat
Slide 5: CINGAL U.S. FDA Update
CINGAL U.S. FDA Update Next Generation Osteoarthritis Therapy Met with the U.S. FDA in Q1 2019; additional Phase III clinical trial required to obtain approval for CINGAL Received formal meeting minutes from the FDA regarding clinical & regulatory pathway Conducting analyses and discussions to ident
Slide 6: Growing Portfolio of Regenerative Treatments
Growing Portfolio of Regenerative Treatments Bone Repair & Rotator Cuff Therapies BONE REPAIR THERAPY Recently showcased at the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting Commercial launch expected in 2H 2019 Plan to utilize hybrid commercial model U.S. market opportunity of $250-
Slide 7: HYALOFAST Update
HYALOFAST Update The Future of Cartilage Regeneration Phase III trial patient enrollment currently at 55% Initiated 37 sites; planning to add new OUS sites and working with all sites to accelerate enrollment High degree of enthusiasm among physicians and patients at the recent Asia Orthopaedic Assoc
Slide 8: Hybrid Commercial Model Update
Hybrid Commercial Model Update Enhancing Visibility and Control to Drive Rapid Growth On track to launch bone repair product in 2H 2019 Pairing a small in-house team of highly-skilled business development specialists with a strategic partner and/or regional distribution partnerships Continuing to ev
Slide 9: Q1 2019 Financial Highlights
Q1 2019 Financial Highlights Strong Start to 2019 Across all Product Franchises Total Revenue Diluted EPS Product Gross Margin (Millions) $0.31 70% 16% $24.7 63% Total Revenue $21.3 $167M Cash & Investments as of ($0.46) 3/31/2019; No debt Q1 2019 Q1 2018 Q1 2019 Q1 2018 Q1 2019 Q1 2018 U.S. Viscosu
Slide 10: Returning Capital to Shareholders While Investing in Growth
Returning Capital to Shareholders While Investing in Growth Announced $50 Million Share Repurchase Program $30 million under Accelerated Share Repurchase (ASR) Program; Up to $20 million will be repurchased on the open market Expect program to commence in mid-May & be completed no later than Q2 2020
Slide 11: Near and Long-Term Growth Drivers
Near and Long-Term Growth Drivers Propelling Transformation into a Global Commercial Company Launch of hybrid commercial model in 2019 -Led by new VP of U.S. Sales International expansion of Orthobiologics franchise - Led by VP of International Sales Continued clinical development of innovative prod
Slide 12: Q&A
Q&A First Quarter 2019 Earnings Call Presentation May 2, 2019